Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Proportionality of TAF in Mucosal Tissue in Women
NCT02357602Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Mar 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV) (3 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Plasma Dose-Proportionality at 14 days, Tissue Dose-Proportionality at 14 days and 1 more. Started Mar 2015; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02357602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02357602.